Cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatitis B co-infection with differential viral suppression.

Zhang, Helen L; Mock, Meredith; Bushman, Lane; Anderson, Peter L; Kiser, Jennifer J; Naggie, Susanna.

Zhang HL; Durham VA Medical Center, Durham, NC, USA.
Mock M; Department of Physician Assistant Studies, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Bushman L; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
Anderson PL; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
Kiser JJ; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
Naggie S; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Clin Infect Dis ; 2024 May 03.

Article en En | MEDLINE | ID: mdl-38703389

ABSTRACT

This case-control study explored cumulative tenofovir exposure among patients with HIV/HBV co-infection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were â¼3-fold lower among patients with incomplete HBV viral suppression (n=4) compared to those with complete suppression (n=5) (516 vs.1456 fmol/punch).

Palabras clave

adherence; antiretroviral therapy; dried blood spots; tenofovir-diphosphate; virologic failure

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article